Issued: November 20, 2019. William Bishop, Supervisory Hearings and Information Officer. [FR Doc. 2019–25500 Filed 11–20–19; 11:15 am] BILLING CODE 7020–02–P

## DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

[Docket No. DEA-550]

Importer of Controlled Substances Application: Janssen Pharmaceuticals, Inc.

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before December 23, 2019. Such persons may also file a written request for a hearing on the application on or before December 23, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

### SUPPLEMENTARY INFORMATION: In

accordance with 21 CFR 1301.34(a), this is notice that on October 9, 2019, Janssen Pharmaceuticals, Inc., 1440 Olympic Drive, Athens, Georgia 30601– 1645 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Thebaine	9333	
Concentrate of Poppy Straw	9670	
Tapentadol	9780	

The company plans to import intermediate forms of tapentadol (9780) and thebaine (9333) for further manufacturing prior to distribution to its customers. The company plans to import concentrate of poppy straw (9670) to bulk manufacture other controlled substances. No other activity for these drug codes is authorized for this registration.

Dated: November 8, 2019. William T. McDermott, Assistant Administrator. [FR Doc. 2019–25407 Filed 11–21–19; 8:45 am] BILLING CODE 4410–09–P

## DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

[Docket No. DEA-551]

## Importer of Controlled Substances Application: Epic Pharma, LLC

#### **ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before December 23, 2019. Such persons may also file a written request for a hearing on the application on or before December 23, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on September 13, 2019, Epic Pharma, LLC, 227–15 North Conduit Avenue, Laurelton, New York 11413, applied to be registered as an importer of the following basic class of controlled substance:

Controlled substance	Drug code	Schedule
Methadone	9250	II

The company plans to import the listed controlled substance for research and analytical purposes.

Dated: November 8, 2019.

## William T. McDermott,

Assistant Administrator. [FR Doc. 2019–25406 Filed 11–21–19; 8:45 am] BILLING CODE 4410–09–P

# DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

[Docket No. DEA-528]

## Importer of Controlled Substances Application: Fresenius Kabi USA, LLC

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before December 23, 2019. Such persons may also file a written request for a hearing on the application on or before December 23, 2019.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Špringfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on August 7, 2019 Fresenius Kabi USA, LLC, 3159 Staley Road, Grand Island, New York 14072–